comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 00:28:15 - browse：569

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Medicare Advantage insurers pressure Biden for bigger payments

hotspot

WSS

Biotech investment managers search for lucrative opportunities

Lack of health data on LGBTQ+ people has serious consequences

IVF doctors demand details after CooperSurgical lawsuit

Adam's Take: Intra

Harvard's David Sinclair gets blowback over aging

This gene therapy has record $4.25 million price. It's saved children.

entertainment

comprehensive

hotspot

The high cost of giving birth even with insurance

Ancient Greek ideas underpin modern concepts of pregnancy

Guidelines to prevent youth baseball injuries need more muscle

He's 19 months old and has one of the world’s rarest diseases

Hepatitis C has a cure — but many Americans still lack access to it

Ozempic has benefits for kidney disease as well as diabetes

Psychedelics group wrestles with new pharma identity

This gene therapy has record $4.25 million price. It's saved children.

In Memoriam: Notable people who died in 2023

IVF doctors demand details after CooperSurgical lawsuit

hotspot

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Readout Newsletter: Illumina, CRISPR, Regeneron

Pfizer, Moderna say biotech, pharma drug development is a sprint

Harvard's David Sinclair gets blowback over aging

CRISPR technology availability, affordability needs to be expanded

First over

hotspot

focus

hotspot

focus